CHU Lyon Sud

Pierre-Bénite 69495

4 studies enrolling now · 8 studies all time

What they study most

Acute Leukemia, Extraintestinal Pathogenic Escherichia Coli Prevention, Indolent Systemic Mastocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Metastatic Castration-resistant Prostate Neoplasms, Myelodysplastic Syndromes, Previously Treated Amyloid Light-chain (AL) Amyloidosis, Relapsed or Refractory Multiple Myeloma, Small Lymphocytic Lymphoma

Studies at this site

• A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) — Recruiting now
• A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting now
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis — Recruiting now
• A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia — Running, not enrolling
• A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health — Completed
• Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome — Stopped early
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis — Completed